It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
about
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaThe National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersA novel quantitative kinase assay using bacterial surface display and flow cytometryMolecular tumor board: the University of California-San Diego Moores Cancer Center experience.Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceUnique molecular landscapes in cancer: implications for individualized, curated drug combinations.N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalThe war on cancer: are we winning?Tumor heterogeneity in the clinic: is it a real problem?Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Busting robustness: using cancer's greatest strength to our advantage.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.A cancer trial scandal and its regulatory backlash.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.The rise of genomic profiling in ovarian cancer.
P2860
Q27026544-25812A34-7A20-4E2D-A1E2-9951A8D22445Q28087174-2744CD6B-1AD3-4D34-9165-C937E3A95428Q28535179-39472511-0544-476F-9BF7-23AD2CB32830Q33699594-492AA1D1-CA6C-4F6D-AA42-BBADD7ACC8B1Q34781347-370336F9-8865-42BD-B51A-11E917316B55Q34938532-9B501D97-55D2-4426-9ADF-C6EE37B1EE35Q35376207-ECB08924-4ACF-4082-B613-FCEB8EAE9D32Q35535953-367C26D3-5FBA-46ED-8CCC-EFC3A45910A9Q36534696-CC20E947-EBE1-4513-BA82-ADBBE99DDE5DQ36544915-7EA21440-F269-4052-8628-9FC2B70C02F1Q36871001-DB516AF5-34AE-4B4E-9E5D-284165CD829EQ38097382-81937642-5A43-420E-8B2E-95BB98EBE704Q38192631-33A8B48A-9A97-4DB7-BA28-A01D2595318DQ38264616-6F9EEF07-84EB-4E97-853F-0C26055EEF7FQ38621094-A4BAE40C-E963-48CD-8039-E7287BBD6754Q38734451-77896008-EFAD-45CB-97BB-280D608519BCQ39221674-8B0B651E-7918-49C9-B356-E3B92B32182BQ40302552-893F196F-535E-4F19-8BD7-F1C5E7398908Q42352191-8CE8AF5B-370C-4805-970B-5D823D724B61Q46349887-DCAAE5BF-71B7-46BB-A1F4-BB7002E55701Q49835188-5D1D6247-28AF-4DB1-BB98-EC32CB29F8FFQ50345037-77682A02-A4BF-4299-9113-D460E713C68D
P2860
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@ast
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@en
type
label
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@ast
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@en
prefLabel
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@ast
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@en
P2860
P1476
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
@en
P2093
Jason R Westin
P2860
P304
P356
10.1158/1535-7163.MCT-12-0473
P577
2012-11-30T00:00:00Z